Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-86.48M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.49 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -26.21% |
| Return on Assets (Trailing 12 Months) | -24.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 23.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 23.81 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.78 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.47 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.51 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.63 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 53.09M |
| Free Float | 44.91M |
| Market Capitalization | $535.68M |
| Average Volume (Last 20 Days) | 0.28M |
| Beta (Past 60 Months) | 1.17 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 84.14% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |